LeAnn Norris

Concepts (159)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Catheter-Related Infections
2
2017
43
0.680
Why?
Hematinics
5
2018
52
0.680
Why?
Catheterization, Central Venous
2
2017
89
0.660
Why?
Anti-Infective Agents
2
2017
166
0.620
Why?
Neoplasms
7
2019
1667
0.500
Why?
Neutropenia
4
2019
72
0.480
Why?
Sepsis
1
2017
233
0.470
Why?
Education, Pharmacy
2
2012
102
0.400
Why?
Antineoplastic Agents
6
2019
1070
0.380
Why?
Education, Distance
1
2009
34
0.340
Why?
Problem-Based Learning
1
2009
72
0.330
Why?
Renal Insufficiency, Chronic
3
2018
161
0.320
Why?
Students, Pharmacy
1
2009
79
0.320
Why?
Granulocyte Colony-Stimulating Factor
3
2013
74
0.320
Why?
Erythropoietin
5
2017
96
0.300
Why?
United States Food and Drug Administration
5
2019
131
0.300
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
2
2019
44
0.300
Why?
Databases, Factual
1
2009
622
0.280
Why?
Red-Cell Aplasia, Pure
2
2018
13
0.270
Why?
Drug Costs
2
2019
87
0.260
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2013
468
0.260
Why?
Leukoencephalopathy, Progressive Multifocal
2
2016
18
0.250
Why?
Anaphylaxis
2
2018
43
0.250
Why?
Anemia
2
2017
104
0.240
Why?
Drug Labeling
4
2017
32
0.230
Why?
Filgrastim
3
2019
22
0.220
Why?
Drug-Related Side Effects and Adverse Reactions
3
2014
148
0.220
Why?
Drug Industry
2
2019
54
0.180
Why?
Drug Utilization
2
2017
119
0.170
Why?
Virus Activation
1
2019
15
0.170
Why?
Hepatitis B, Chronic
1
2019
19
0.170
Why?
Pyrazoles
2
2019
190
0.160
Why?
Pyrimidines
2
2019
178
0.160
Why?
Root Cause Analysis
1
2018
2
0.160
Why?
Biosimilar Pharmaceuticals
1
2019
25
0.160
Why?
Cost Savings
1
2019
110
0.160
Why?
Humans
26
2019
68618
0.150
Why?
Natalizumab
1
2017
6
0.150
Why?
Protein Kinase Inhibitors
2
2019
331
0.150
Why?
Antiviral Agents
1
2019
211
0.150
Why?
Hemorrhage
1
2019
328
0.140
Why?
Neoplasms, Second Primary
1
2017
62
0.140
Why?
Drugs, Generic
1
2016
17
0.140
Why?
Immunologic Factors
1
2017
87
0.140
Why?
Multiple Sclerosis
1
2017
132
0.130
Why?
Medicaid
1
2017
302
0.120
Why?
Drugs, Investigational
1
2014
18
0.120
Why?
Peptides
2
2018
455
0.120
Why?
Immunoconjugates
1
2014
26
0.120
Why?
Melanoma
1
2017
335
0.110
Why?
Lymphoma
1
2013
116
0.110
Why?
Heparin
1
2013
205
0.110
Why?
Fever
1
2013
96
0.110
Why?
Epoetin Alfa
3
2018
23
0.110
Why?
Reye Syndrome
1
2012
11
0.100
Why?
Primary Prevention
1
2013
115
0.100
Why?
Thalidomide
1
2012
24
0.100
Why?
Nephrogenic Fibrosing Dermopathy
1
2012
7
0.100
Why?
Off-Label Use
1
2012
17
0.100
Why?
Recombinant Proteins
4
2017
742
0.100
Why?
Biostatistics
1
2012
43
0.100
Why?
Angiogenesis Inhibitors
1
2012
64
0.100
Why?
United States
7
2019
7367
0.100
Why?
Taxoids
1
2011
41
0.100
Why?
Prostatic Neoplasms
1
2017
778
0.090
Why?
Premedication
1
2011
49
0.090
Why?
Adverse Drug Reaction Reporting Systems
1
2011
42
0.090
Why?
Darbepoetin alfa
3
2017
13
0.090
Why?
Paclitaxel
1
2011
140
0.090
Why?
Incidence
3
2019
1603
0.090
Why?
Comprehension
1
2009
71
0.080
Why?
Chlorhexidine
1
2008
12
0.080
Why?
Ulcer
1
2008
27
0.080
Why?
Anti-Infective Agents, Local
1
2008
40
0.080
Why?
Dermatologic Agents
1
2008
32
0.080
Why?
Methotrexate
1
2008
91
0.080
Why?
Psoriasis
1
2008
46
0.080
Why?
Adenine
2
2019
46
0.080
Why?
Piperidines
2
2019
123
0.070
Why?
Female
11
2019
38074
0.070
Why?
Internet
1
2009
390
0.070
Why?
Aphasia
1
2008
119
0.070
Why?
Health Knowledge, Attitudes, Practice
1
2012
767
0.070
Why?
Drug Approval
2
2019
50
0.070
Why?
Acute Kidney Injury
1
2008
232
0.070
Why?
Treatment Outcome
1
2017
7029
0.060
Why?
Middle Aged
7
2017
21147
0.060
Why?
Anticoagulants
2
2019
356
0.060
Why?
Male
8
2019
37321
0.050
Why?
Polyethylene Glycols
2
2013
149
0.050
Why?
Ethanol
1
2008
893
0.050
Why?
Surveys and Questionnaires
1
2009
2800
0.050
Why?
Aged
4
2019
14862
0.050
Why?
Alcoholism
1
2008
1109
0.040
Why?
Coinfection
1
2019
30
0.040
Why?
Risk Factors
2
2019
5731
0.040
Why?
Hematologic Agents
1
2019
11
0.040
Why?
Virus Replication
1
2019
104
0.040
Why?
Japan
1
2019
68
0.040
Why?
Tungsten
1
2018
3
0.040
Why?
Preservatives, Pharmaceutical
1
2018
4
0.040
Why?
Excipients
1
2018
8
0.040
Why?
Syringes
1
2018
15
0.040
Why?
Injections, Subcutaneous
1
2018
87
0.040
Why?
Europe
1
2019
196
0.040
Why?
Drug Hypersensitivity
1
2018
35
0.040
Why?
Veterans Health
1
2019
62
0.040
Why?
Hepatitis C, Chronic
1
2019
86
0.040
Why?
Injections, Intravenous
1
2018
215
0.040
Why?
Canada
1
2019
267
0.040
Why?
South Carolina
2
2017
2752
0.040
Why?
Erythropoiesis
1
2017
24
0.040
Why?
United States Department of Veterans Affairs
1
2019
307
0.040
Why?
Adult
4
2017
21403
0.040
Why?
Therapeutic Equivalency
1
2016
21
0.040
Why?
Drug and Narcotic Control
1
2016
15
0.040
Why?
Platelet Aggregation Inhibitors
1
2019
373
0.030
Why?
SEER Program
1
2017
153
0.030
Why?
Medicare
1
2017
319
0.030
Why?
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
2014
2
0.030
Why?
Hodgkin Disease
1
2014
27
0.030
Why?
Mycosis Fungoides
1
2014
16
0.030
Why?
Drug Incompatibility
1
2013
7
0.030
Why?
Drug Stability
1
2013
71
0.030
Why?
Drug Compounding
1
2013
34
0.030
Why?
Young Adult
2
2017
5717
0.030
Why?
Mass Screening
1
2019
843
0.030
Why?
Logistic Models
1
2017
1420
0.030
Why?
Hemoglobins
1
2013
120
0.030
Why?
Connecticut
1
2012
13
0.030
Why?
Lawyers
1
2012
4
0.030
Why?
Lymphoma, Large B-Cell, Diffuse
1
2013
47
0.030
Why?
Lobbying
1
2012
11
0.030
Why?
Hematology
1
2012
10
0.030
Why?
Drug Discovery
1
2013
94
0.030
Why?
Public Opinion
1
2012
32
0.030
Why?
Colorectal Neoplasms
1
2017
561
0.020
Why?
Gadolinium
1
2012
88
0.020
Why?
Venous Thromboembolism
1
2012
117
0.020
Why?
Data Collection
1
2012
420
0.020
Why?
Aspirin
1
2012
295
0.020
Why?
Educational Measurement
1
2012
254
0.020
Why?
Survival Rate
1
2012
1056
0.020
Why?
Hand Disinfection
1
2008
9
0.020
Why?
Lung Neoplasms
1
2017
1173
0.020
Why?
Eating
1
2008
119
0.020
Why?
Practice Guidelines as Topic
1
2013
772
0.020
Why?
Research Design
1
2012
729
0.020
Why?
Drug Overdose
1
2008
67
0.020
Why?
Aged, 80 and over
1
2017
4848
0.020
Why?
Prevalence
1
2012
1619
0.020
Why?
Breast Neoplasms
1
2017
1536
0.020
Why?
Inpatients
1
2008
208
0.020
Why?
Prognosis
1
2012
2093
0.020
Why?
Risk Assessment
1
2012
2007
0.020
Why?
Time Factors
1
2013
4655
0.020
Why?
Cohort Studies
1
2011
2358
0.020
Why?
Quality of Life
1
2013
1515
0.020
Why?
Adolescent
1
2017
8912
0.010
Why?
Norris's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (159)
Explore
_
Co-Authors (9)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_